GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lincoln Pharmaceuticals Ltd (NSE:LINCOLN) » Definitions » Debt-to-Asset

Lincoln Pharmaceuticals (NSE:LINCOLN) Debt-to-Asset : 0.00 (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Lincoln Pharmaceuticals Debt-to-Asset?

Lincoln Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Lincoln Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Lincoln Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was ₹0 Mil.


Lincoln Pharmaceuticals Debt-to-Asset Historical Data

The historical data trend for Lincoln Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lincoln Pharmaceuticals Debt-to-Asset Chart

Lincoln Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 - - - -

Lincoln Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lincoln Pharmaceuticals's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Lincoln Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lincoln Pharmaceuticals's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lincoln Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Lincoln Pharmaceuticals's Debt-to-Asset falls into.


;
;

Lincoln Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Lincoln Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Mar. 2024 is calculated as

Lincoln Pharmaceuticals's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lincoln Pharmaceuticals  (NSE:LINCOLN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Lincoln Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Lincoln Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Lincoln Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Science City Road, Lincoln House, Behind Satyam Complex, Sola, Ahmedabad, GJ, IND, 380060
Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.

Lincoln Pharmaceuticals Headlines

No Headlines